Archive
This is my archive
Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and Commercialize Small Molecule GLP-1 Receptor Agonist ECC5004 for Cardiometabolic Diseases
Eccogene will receive initial upfront payment of $185 million. Eccogene is also eligible to receive up to $1.825 billion in future clinical, regulatory, and commercial milestones, as well as royalty payments. AstraZeneca will receive an exclusive license to develop and commercialize ECC5004 in all territories except China. In China, Eccogene and AstraZeneca will partner for… Read More
Phanes Therapeutics, Inc. Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate PT886 in Combination with KEYTRUDA® (pembrolizumab)
PT886 is Phanes’ first-in-class bispecific antibody targeting claudin 18.2 and CD47; KEYTRUDA® (pembrolizumab) is Merck’s anti-PD-1 The clinical trial collaboration will focus on evaluating PT886 in combination with KEYTRUDA® for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas PT886 is also being studied for the treatment of pancreatic cancer… Read More
PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
SAN DIEGO, March 6, 2023 /PRNewswire/ — Phanes Therapeutics, Inc., a clinical stage biotech company focused on innovative drug discovery and development in oncology, today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company. The collaboration will leverage Phanes’ proprietary technology platforms, PACbody™ and… Read More
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
Allecra receives upfront, development and commercial milestone payments, in addition to double-digit royalties ADVANZ gains commercial rights for cefepime/enmetazobactam in the European Union, the United Kingdom, Switzerland, and Norway Cefepime/enmetazobactam has completed a Phase III clinical trial against standard of care in treating complicated urinary tract infection, including acute pyelonephritis1… Read More
Clover Announces Advance Purchase Agreement with Gavi for Over 400 Million Doses of Clover’s COVID-19 Vaccine for the COVAX Facility
Pending WHO EUL for its COVID-19 vaccine candidate, Clover is committed to providing 64 million doses in 2021 and Gavi has options for an additional 350 million doses in 2022 Clover will receive a significant upfront payment, a payment upon positive Phase 2/3 data, potential payments upon option exercise and… Read More
Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
December 21, 2020 02:00 ET | Source: Allecra Therapeutics GmbH; Shanghai Haini Pharmaceutical Co., Ltd. Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with… Read More
CEPI Expands Partnership with Clover to Rapidly Advance Development and Manufacture of COVID-19 Vaccine Candidate
CEPI to invest an additional $66m upfront in Clover’s S-Trimer protein vaccine candidate. Funding will support clinical development in parallel with scale-up of manufacturing capacity to potentially produce hundreds of millions of doses per year. July 08, 2020 04:00 AM Eastern Daylight Time OSLO, Norway–(BUSINESS WIRE)–CEPI, the Coalition… Read More
GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
Clover Biopharmaceuticals initiates phase 1 study using GSK pandemic adjuvant in combination with COVID-19 vaccine candidate SCB-2019 GSK’s scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover today announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19… Read More
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
CHENGDU, China, London, UK – 24 February 2020 – Clover Biopharmaceuticals, a China based global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced today that it has entered into a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer). GSK will provide Clover with its pandemic adjuvant… Read More